Akero Therapeutics, Inc. Banner Image

Akero Therapeutics, Inc. has reached its limit for free report views

Work for Akero Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Akero Therapeutics, Inc.

  • Ticker AKRO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Akero Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in South San Francisco, California
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is headquartered in South SanMore Francisco, CA.
4.8 / 5.0 (198)

Akero Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 198 reviews.

Akero Therapeutics, Inc.

Most Recent Annual Report

Akero Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. Akero Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Akero Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!